Comparing live attenuated and inactivated hepatitis A vaccines: An immunogenicity study after one single dose

Vaccine

Volumn 29, Issue 48, 2011, Pages 9098-9103

  Zheng, Hui ^a   Chen, Yuansheng ^a   Wang, Fuzhen ^a   Gong, Xiaohong ^a   Wu, Zhenhua ^a   Miao, Ning ^a   Zhang, Xiaoshu ^b   Li, Hui ^b   Chen, Chao ^c   Hou, Xiang ^c   Cui, Fuqiang ^a   Wang, Huaqing ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b GANSU PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Jilin Provincial Center for Disease Control and Prevention   (China)

Author keywords

Hepatitis A vaccine; Immunogenicity

Indexed keywords

HEALIVE; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; INACTIVATED VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CHILD; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG FEVER; DRUG SAFETY; FEMALE; HEPATITIS A; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SELF REPORT; SEROCONVERSION; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE;

ADOLESCENT; ANTIBODY FORMATION; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HUMANS; MALE; SINGLE-BLIND METHOD; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 82455188095     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.078     Document Type: Article

References (34)

1. Karayiannis P., Main J., Thomas H.C. Hepatitis vaccines. Br Med Bull 2004, 70:29-49.
2. Bryan J.P., Henry C.H., Hoffman A.G., South-Paul J.E., Smith J.A., Cruess D., et al. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 2001, 19(7-8):743-750.
3. Tilzey A.J., Palmer S.J., Barrow S., Perry K.R., Tyrrell H., Safary A., et al. Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. BMJ 1992, 304(6837):1272-1276.
4. ® Merck) in children and adults. Vaccine 2002, 22(5-6):766-772.
5. ® in adults: safety, tolerability, and immunogenicity. Vaccine 2001, 19(32):4727-4731.
6. Braconier J.H., Wennerholm S., Norrby S.R. Comparative immunogenicity and tolerance of Vaqta and Havrix. Vaccine 1999, 17(17):2181-2184.
7. Ashur Y., Adler R., Rowe M., Shouval D. Comparison of immunogenicity of two hepatitis A vaccines-VAQTA and HAVRIX1 in young adults. Vaccine 1999, 17(18):2290-2296.
8. Clarke P., Kitchin N., Souverbie F. A randomized comparison of two inactivated hepatitis A vaccines, Avaxim™ and Vaqta™, given as a booster to subjects primed with Avaxim™. Vaccine 2001, 19(31):4429-4433.
9. Andre F.E. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 2001, 20(3-4):292-293.
10. Bialek S.R., Thoroughman D.A., Hu D., Simard E.P., Chattin J., Cheek J., et al. Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska natives, 1990-2001. Am J Public Health 2004, 94(6):996-1001.
11. Shen Y.G., Gu X.J., Zhou J.H. Protective effect of inactivated hepatitis A vaccine against the outbreak of hepatitis A in an open rural community. World J Gastroenterol 2008, 14(17):2771-2775.
12. Victor J.C., Monto A.S., Surdina T.Y., Suleimenova S.Z., Vaughan G., Nainan O.V., et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007, 357(17):1685-1694.
13. Wang X.Y., Xu Z.Y., Ma J.C., von Seidlein L., Zhang Y., Hao Z.Y., et al. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up. Vaccine 2007, 25(3):446-449.
14. Gong J., Luo D., Liu J.Y., Li R.C., Wang P.F., Huang J.C., et al. Comparison of two-year follow-up immunogenicity between live attenuated hepatitis A vaccine and imported inactivated vaccine. China Public Health 2002, 18(12):1412-1413.
15. Zhuang H. The hepatitis A vaccines and the immunization strategy. Chin J Epidemiol 2007, 28(1):1-4.
16. Liu L., Xv Z.Y., Yang P.Y., Zhao S.J., Wu W.Z. Research on reimmunization with live attennuated hepatitis A vaccine. Chin J Prev Med 1998, 32(3):162-164.
17. Xv Z.Y.i, Wang X.Y., Zhao S.J. The immunogenicity and strategy of the live attenuated hepatitis A vaccine. Chin J Prev Med 2002, 36(3):199-201.
18. Ren A.G., Feng F.M., Ma J.R., Xv Y.J., Liu C.B. Immunogenicity and safety of a new inactivated hepatitis A vaccine in young adults: a comparative study. Chin Med J (Engl) 2002, 115(10):1483-1485.
19. ®. Chin J Vaccine Immunization 2003, 9(4):219-221.
20. Ren A.G., Ma J.R., Fenf F.M., Xv Y.J., Liu C.B. Safety and immunogenicity of a new inactivated hepatitis A vaccine. Chin J Exp Clin Virol 2001, 15(4):357-359.
21. Cui F., Hadler S.C., Zheng H., Wang F., Zhenhua W., Yuansheng H., et al. Surveillance and vaccine use in China from 1990 through 2007. J Epidemiol 2009, 19(4):189-195.
22. World Health Organization The immunological basis for immunization series: module 18: hepatitis A 2011, WHO Document Production Services, Geneva, Switzerland.
23. Balcarek K.B., Bagley M.R., Pass R.F., Schiff E.R., Krause D.S. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. Infect Dis 1995, 171(Suppl. 1):S70-S72.
24. Horng Y.C., Chang M.H., Lee C.Y., Safary A., Andre F.E., Chen D.S. Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis 1993, 12:359-362.
25. Zhang X.C., Han L.L., Xing Y.L., Zhou S.L., Chen C.S., Liu M.X. A study on immune effects of hepatitis A vaccines of different persons with different schedules. Chin J Vaccine Immunization 2002, 8(5):254-257.
26. Ren Y.H., Wu W.T., Zhang Y.C., Xue W.H., Kang W.C., Ren Y.F., et al. The study on immunization of low-dose inactivated Chinese hepatitis A vaccine. Chin J Vaccine Immunization 2003, 9(2):114-116.
27. Jia Xy, Liu D., Lv Z.Z., Zheng P., Zhang X.M., Gao X.Q., et al. Study on safety and immunogenicity of heal ive inactivated hepatitis A vaccine used among children. Chin J Epidemiol 2004, 10(4):213-214.
28. Huang G.B., Wan C.J., Li R.C., Huang Q.M., Gao J.M., Li Y.P., et al. The immunogenicity and safety of Chinese attenuated hepatitis A vaccine. Chin J Epidemiol 2003, 24(4):328-329.
29. Ren Y.H., Chen J.T., Ma S.D., Xue W.H., Zhang Y.C., Wu W.T., et al. The study on immunogenicity of low-dose inactivated domestic HAV vaccine. Chin J Vaccine Immunization 2002, 8(6):327-329.
30. Zhang X.C., Han L.L., Xing Y.L., Zhou S.L., Chen C.S., Liu M.S. A study on immune effects of hepatitis A vaccines to different persons with different schedules. Chin J Vaccine Immunization 2002, 8(5):254-257.
31. Zhang Y.L., Ma J.C., Wu S.H., Han C.H., Liu H.W., Zhang Y.W., et al. Observation of the immune effect of an immunizing schedule of 0, 12 months of the live attenuated hepatitis A vaccine, H2 strain. Chin J Vaccine Immunization 2001, 7(3):144-145.
32. Wang X.Y., Xv Z.Y., Ma J.C., Seidlein L.V., Zhang Y., Hao Z.Y., et al. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up. Vaccine 2007, 25(3):446-449.
33. Liu C.B., Ren Y.H., Zhang Y.C., Wu W.T., Li S.P., Kang W.X., et al. The study on immunogenicity, safety and vaccine schedule of a new inactivated hepatitis A vaccine in Chinese children. Chin J Vaccine Immunization 2002, 8(1):1-3.
34. Zhao L. The immunogenicity and safety of a live attenuated hepatitis A vaccine. Modern Prev Med 2007, 35(15):2960.